These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 31552606)

  • 1. CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms.
    Roselli E; Frieling JS; Thorner K; Ramello MC; Lynch CC; Abate-Daga D
    BioDrugs; 2019 Dec; 33(6):647-659. PubMed ID: 31552606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The making and function of CAR cells.
    Zabel M; Tauber PA; Pickl WF
    Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
    Hughes-Parry HE; Cross RS; Jenkins MR
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
    Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
    Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
    Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuning the performance of CAR T cell immunotherapies.
    Richardson NH; Luttrell JB; Bryant JS; Chamberlain D; Khawaja S; Neeli I; Radic M
    BMC Biotechnol; 2019 Nov; 19(1):84. PubMed ID: 31783836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
    Lee YH; Kim CH
    Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
    Cushman-Vokoun AM; Voelkerding KV; Fung MK; Nowak JA; Thorson JA; Duncan HL; Kalicanin T; Anderson MW; Yohe S
    Arch Pathol Lab Med; 2021 Jun; 145(6):704-716. PubMed ID: 33237994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics.
    Gorovits B; Koren E
    BioDrugs; 2019 Jun; 33(3):275-284. PubMed ID: 31069709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Navigating CAR-T cells through the solid-tumour microenvironment.
    Hou AJ; Chen LC; Chen YY
    Nat Rev Drug Discov; 2021 Jul; 20(7):531-550. PubMed ID: 33972771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs.
    Balagopalan L; Moreno T; Qin H; Angeles BC; Kondo T; Yi J; McIntire KM; Alvinez N; Pallikkuth S; Lee ME; Yamane H; Tran AD; Youkharibache P; Cachau RE; Taylor N; Samelson LE
    Sci Signal; 2024 Jul; 17(846):eadp8569. PubMed ID: 39042728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.